Showing 671-680 of 3326 results for "".
A Case of Orf; Creating a Business Plan
https://practicaldermatology.com/youngmd-connect/resident-resource-center/a-case-of-orf-creating-a-business-plan/20675/A Non-Invasive 2-Gene Molecular Assay Shows Promise in Assessment of Pigmented Lesions
https://practicaldermatology.com/topics/skin-cancer-photoprotection/a-non-invasive-2-gene-molecular-assay-shows-promise-in-assessment-of-pigmented-lesions/20705/More studies are needed, but a non-invasive assay that identified melanoma gene expression could support clinical decision making.New Products
https://practicaldermatology.com/columns/new-products/new-products/20764/Phototherapy's Role in the Shifting Spectrum of Psoriasis Care
https://practicaldermatology.com/topics/psoriasis/phototherapys-role-in-the-shifting-spectrum-of-psoriasis-care/21087/Phototherapy has been pushed to the fringe of psoriasis treatment, but new research and innovation in delivery suggest it deserves its place in the changing treatment paradigm.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21137/Managing High Maintenance Clients
https://practicaldermatology.com/topics/practice-management/managing-high-maintenance-clients/21240/Adopt a strategic approach to minimize the negative impact of difficult patients and nurture positive2014 Fourth Quarter Tax Saving Tips
https://practicaldermatology.com/topics/practice-management/2014-fourth-quarter-tax-saving-tips/21294/What to do now to save $10,000-$25,000 or more on your 2014 taxes.The Best Asset Protection Implementation is Not Asset Protection... Is Yours?
https://practicaldermatology.com/topics/practice-management/the-best-asset-protection-implementation-is-not-asset-protection-is-yours/21472/A review of plans that will offer protection if needed and help build wealth along the way.First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.Backdoor Roth IRA Strategy
https://practicaldermatology.com/topics/practice-management/backdoor-roth-ira-strategy/20428/An effective step toward tax diversification.